These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15762885)
1. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire. Ondoa P; Koblavi-Dème S; Borget MY; Nolan ML; Nkengasong JN; Kestens L Clin Exp Immunol; 2005 Apr; 140(1):138-48. PubMed ID: 15762885 [TBL] [Abstract][Full Text] [Related]
2. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy. Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605 [TBL] [Abstract][Full Text] [Related]
3. HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement. Lubaki NM; Shepherd ME; Brookmeyer RS; Hon H; Quinn TC; Kashamuka M; Johnson M; Gottle R; Devers J; Lederman HM; Bollinger RC J Acquir Immune Defic Syndr; 1999 Sep; 22(1):19-30. PubMed ID: 10534143 [TBL] [Abstract][Full Text] [Related]
4. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression. Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319 [TBL] [Abstract][Full Text] [Related]
5. Association of CD8+ T lymphocyte subsets with the most commonly used markers to monitor HIV type 1 infection in children treated with highly active antiretroviral therapy. Navarro J; Resino S; Bellón JM; Abad ML; Gurbindo D; Fernández-Cruz E; Muñóz-Fernández MA AIDS Res Hum Retroviruses; 2001 Apr; 17(6):525-32. PubMed ID: 11350666 [TBL] [Abstract][Full Text] [Related]
6. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481 [TBL] [Abstract][Full Text] [Related]
7. Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy. d'Ettorre G; Ceccarelli G; Serafino S; Giustini N; Cavallari EN; Bianchi L; Pavone P; Bellelli V; Turriziani O; Antonelli G; Stroffolini T; Vullo V J Med Virol; 2016 Aug; 88(8):1347-56. PubMed ID: 26765625 [TBL] [Abstract][Full Text] [Related]
8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression. Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945 [TBL] [Abstract][Full Text] [Related]
9. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART. Beran O; Holub M; Spála J; Kalanin J; Stanková M Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479 [TBL] [Abstract][Full Text] [Related]
10. CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. Doisne JM; Urrutia A; Lacabaratz-Porret C; Goujard C; Meyer L; Chaix ML; Sinet M; Venet A J Immunol; 2004 Aug; 173(4):2410-8. PubMed ID: 15294954 [TBL] [Abstract][Full Text] [Related]
11. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778 [TBL] [Abstract][Full Text] [Related]
12. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy. Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953 [TBL] [Abstract][Full Text] [Related]
13. Impact of suppression of viral replication by highly active antiretroviral therapy on immune function and phenotype in chronic HIV-1 infection. Lange CG; Lederman MM; Madero JS; Medvik K; Asaad R; Pacheko C; Carranza C; Valdez H J Acquir Immune Defic Syndr; 2002 May; 30(1):33-40. PubMed ID: 12048361 [TBL] [Abstract][Full Text] [Related]
14. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. Bofill M; Mocroft A; Lipman M; Medina E; Borthwick NJ; Sabin CA; Timms A; Winter M; Baptista L; Johnson MA; Lee CA; Phillips AN; Janossy G AIDS; 1996 Jul; 10(8):827-34. PubMed ID: 8828739 [TBL] [Abstract][Full Text] [Related]
16. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M AIDS; 1998 Nov; 12(16):2115-23. PubMed ID: 9833852 [TBL] [Abstract][Full Text] [Related]
17. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102 [TBL] [Abstract][Full Text] [Related]
18. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338 [TBL] [Abstract][Full Text] [Related]
19. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G; AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002 [TBL] [Abstract][Full Text] [Related]
20. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection. Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]